Stay updated with breaking news from Early Mortality. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Calysta’s FeedKind has received formal approval for use in aquafeeds in China as the company’s joint venture prepares to deliver first product to customers
Breakthrough treatment reduces new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, fibrodysplasia...
Breakthrough treatment reduces new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, fibrodysplasia ossificans progressiva FOP impacts about 400... -Today at 03:33 pm- MarketScreener
A posthoc analysis of the pivotal SOLOIST-WHF trial provides insight into the effects of sotagliflozin use on risk of cardiovascular mortality and heart failure readmissions at 90 days.
Ultra-Processed Diets: A recent study involving more than 1,000 people with type 2 diabetes in Italy has raised concerns.